D. H. Nguyen et al. / Bioorg. Med. Chem. 9 (2001) 7±17
15
combined in 2 mL of DMF. DIEA (1 mL) was then
added and the reaction mixture allowed to stand for
5 min. The activated monomer was added to the reac-
tion vessel, containing NH2-Py-g-ImPyPyPy-b-Pam-
resin, and the coupling was allowed to proceed for 20 h
at 37 ꢁC before termination with acetic anhydride. After
Boc-deprotection of the resin-bound polyamide chain,
the Boc-Im-OH was activated with HBTU/DIEA as
previously described and coupled onto NH2-PzPy-g-
ImPyPyPy-b-Pam-resin at 37 ꢁC for 24 h. The terminal
imidazole was incorporated as previously published. A
sample of ImImPzPy-g-ImPyPyPy-b-Pam-resin (300 mg,
0.44 mmol/g) was placed in a 20 mL scintillation vial,
2 mL of dimethylaminopropylamine was added, and the
mixture was allowed to stand at 55 ꢁC for 18 h. Resin
was removed through ®ltration through a disposable
propylene ®lter, and the resulting solution diluted with
water to a total volume of 8 mL and puri®ed directly by
reversed phase HPLC to provide ImImPzPy-g-ImPy-
PyPy-b-Dp (2) (5.7 mg, 3.5% recovery) as a white pow-
der upon lyophilization of the appropriate fractions. 1H
NMR (DMSO-d6) d 10.47 (s, 1H), 10.29 (s, 1H), 10.14
(s, 1H), 10.04 (s, 1H), 10.02 (s, 1H), 9.97 (s, 1H), 9.92 (s,
1H), 9.25 (br s, 1H), 8.1 (m, 3H), 7.68 (s, 1H), 7.48 (s,
2H), 7.43 (s, 1H), 7.28 (s, 1H), 7.2 (m, 2H), 7.18 (s, 2H),
7.11 (s, 1H), 7.08 (s, 1H), 6.96 (s, 1H), 6.89 (s, 1H), 4.06
(s, 3H), 4.04 (s, 3H), 4.02 (s, 3H), 3.97 (s, 3H), 3.87 (s,
3H), 3.85 (s, 3H), 3.83 (s, 3H), 3.81 (s, 3H), 3.4 (m, 2H),
3.2 (m, 2H), 3.1 (m, 2H), 3.0 (m, 2H), 2.7 (m, 6H), 2.4
(m, 4H), 1.8 (m, 4H); MALDI-TOF-MS (mono-
isotopic), 1224.63 (1224.57 calcd for M+H).
solution puri®ed directly by preparatory reversed phase
HPLC to provide 2E as a white powder (3.6 mg, 36%
recovery). MALDI-TOF-MS (monoisotopic), 1542.16
(1542.81 calcd for M+H).
ImImThPy-ꢀ-ImPyPyPy-ꢁ-Dp (3). ImImPzPy-g-ImPy-
PyPy-b-Pam-resin was synthesized in a stepwise fashion
by manual solid-phase protocols25 from Boc-b-alanine-
Pam-resin (1.0 g, 0.75 mmol/g). Boc-Th-OH (258 mg,
1 mmol) and HBTU (360 mg, 0.95 mmol) were com-
bined in 2 mL of DMF. DIEA (1 mL) was then added
and the reaction mixture allowed to stand for 5 min.
The activated monomer was added to the reaction ves-
sel, containing NH2-Py-g-ImPyPyPy-b-Pam-resin, and
the coupling was allowed to proceed for 20 h at 37 ꢁC
before termination with acetic anhydride. After Boc-
deprotection of the resin-bound polyamide chain, the
Boc-Im-OH was activated with HBTU/DIEA as pre-
viously described and coupled onto NH2-ThPy-g-
ImPyPyPy-b-Pam-resin at 37 ꢁC for 40 h. The terminal
imidazole was incorporated as previously published. A
sample of resin (150 mg, 0.43 mmol/g) was placed in a
20 mL scintillation vial, 2 mL of dimethylaminopropyl-
amine was added, and the mixture was allowed to stand
at 55 ꢁC for 18 h. Resin was removed by ®ltration
through a disposable polypropylene ®lter, and the
resulting solution diluted with water to a total volume
of 8 mL and puri®ed directly by reversed phase HPLC
to provide ImImThPy-g-ImPyPyPy-b-Dp (1.5 mg, 1.8%
recovery) as a white powder upon lyophilization of the
1
appropriate fractions. H NMR (DMSO-d6) d 10.29 (s,
1H), 10.05 (s, 1H), 10.02 (s, 1H), 9.98 (s, 3H), 9.92 (s,
1H), 9.2 (br s, 1H), 8.1 (m, 3H), 7.78 (s, 1H), 7.49 (s,
2H), 7.32 (s, 1H), 7.28 (s, 1H), 7.26 (s, 1H), 7.24 (s, 2H),
7.18 (s, 1H), 7.10 (s, 1H), 6.9 (m, 2H), 3.99 (s, 3H), 3.97
(s, 3H), 3.91 (s, 3H), 3.82 (s, 3H), 3.80 (s, 3H), 3.7 (m,
9H), 3.4 (m, 2H), 3.2 (m, 2H), 3.1 (m, 2H), 3.0 (m, 2H),
2.7 (m, 6H), 2.4 (m, 4H), 1.8 (m, 4H); MALDI-TOF-
MS (monoisotopic), 1241.67 (1241.53 calcd for M+H).
ImImPzPy-ꢀ-ImPyPyPy-ꢁ-Dp-NH2 (2-NH2). A sample
of ImImPzPy-g-ImPyPyPy-b-Pam-resin (250 mg, 0.44
mmol/g) was placed in a 20 mL scintillation vial, 2 mL
of 3,30-diamino-N-methyldipropylamine was added, and
the mixture was allowed to stand at 55 ꢁC for 18 h.
Resin was removed through ®ltration through a dis-
posable propylene ®lter, and the resulting solution dilu-
ted with water to a total volume of 8 mL and puri®ed
directly by reversed phase HPLC to provide ImImPzPy-
g-ImPyPyPy-b-Dp-NH2 (2-NH2) (8.2 mg, 5.9% recov-
ery) as a white powder upon lyophilization of the
DNA reagents and materials
Enzymes were purchased from Boehringer±Mannheim
and used with their supplied buers. Deoxyadenosine and
thymidine 50-[a-32P] triphosphates were obtained from
Dupont/NEN. Calf thymus DNA (sonicated, deprotein-
ized), DNase I (7500 u/mL, FPLC pure), Tris±HCl,
dithiothreitol (DTT), RNase-free water (used for all
footprinting and anity cleavage reactions), and 0.5 M
EDTA were purchased from Amersham Pharmacia.
XGal and IPTG were from ICN. Ampicillin trihydrate
was acquired from Sigma. Absolute ethanol was pur-
chased from Equistar. Calcium chloride, potassium
chloride, and magnesium chloride were from Fluka.
Formamide and pre-mixed Tris-borate±EDTA (Gel-
Mate) were from Gibco. All reagents were used without
further puri®cation. DNA manipulations were per-
formed according to standard protocols.36
1
appropriate fractions. H NMR (DMSO-d6) d 10.47 (s,
1H), 10.29 (s, 1H), 10.14 (s, 1H), 10.03 (s, 2H), 9.98 (s,
1H), 9.92 (s, 1H), 9.25 (br s, 1H), 8.1 (m, 3H), 7.82 (br s,
3H), 7.68 (s, 1H), 7.48 (s, 2H), 7.43 (s, 1H), 7.29 (s, 2H),
7.2 (m, 1H), 7.18 (s, 1H), 7.1 (m, 2H), 6.95 (s, 2H), 6.90
(s, 1H), 4.06 (s, 3H), 4.04 (s, 3H), 4.02 (s, 3H), 3.97 (s,
3H), 3.87 (s, 3H), 3.85 (s, 3H), 3.83 (s, 3H), 3.81 (s, 3H),
3.2±3.0 (m, 8H), 2.9 (m, 2H), 2.5 (m, 4H), 2.37 (br s,
4H), 2.0±1.7 (br m, 6H); MALDI-TOF-MS (mono-
isotopic), 1267.78 (1267.61 calcd for M+H).
ImImPzPy-ꢀ-ImPyPyPy-ꢁ-Dp-EDTA (2E). EDTA-di-
anhydride (50 mg) was dissolved in 1 mL of DMSO/
NMP solution and 1 mL of DIEA by heating at 55 ꢁC
for 5 min. The dianhydride solution was added to Im-
ImPzPy-g-ImPyPyPy-b-Dp-NH2 (2-NH2) (8.2 mg, 6.5
mmol) dissolved in 750 mL of DMSO. The mixture was
heated to 55 ꢁC for 25 min, treated with 3 mL of 0.1 N
NaOH, and heated to 55 ꢁC for 10 min. TFA (0.1%)
was added to adjust the total volume to 8 mL, and the
Construction of plasmid DNA
The plasmid pDHN1 was prepared by hybridization of
a complementary set of synthetic oligonucleotides: 50-